Medicaid coverage for weight loss medications varies dramatically by state, and most states don’t cover them at all when prescribed solely for obesity. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications like Wegovy and Zepbound for weight loss. A long-standing federal law allows states to opt out of covering weight loss drugs, making this one of the biggest gaps in Medicaid’s drug coverage.
Why Coverage Depends on Your State
Medicaid programs are required to cover nearly all FDA-approved drugs, but weight loss medications are a specific exception. Federal law gives each state the choice of whether to include them. This means your neighbor across a state line might have full access to the same drug your Medicaid plan won’t touch.
The number of states offering coverage has actually been shrinking. In October 2025, 16 state Medicaid programs covered GLP-1 drugs for obesity. By January 2026, four states (California, New Hampshire, Pennsylvania, and South Carolina) had dropped that coverage, largely because of budget pressures and the high cost of these medications. North Carolina briefly eliminated coverage due to a legislative budget stalemate but reinstated it in December 2025.
What Your Diagnosis Changes
The diagnosis your doctor uses on the prescription matters enormously. While states can refuse to cover weight loss drugs prescribed for obesity, they are required to cover drugs approved for type 2 diabetes. Several popular medications straddle both categories, and the reason your doctor prescribes one determines whether Medicaid pays for it.
Here’s how the major drugs break down by their FDA-approved uses:
- Ozempic (semaglutide): Approved for type 2 diabetes and cardiovascular risk reduction. Not approved for weight loss. Medicaid must cover it when prescribed for diabetes.
- Mounjaro (tirzepatide): Approved for type 2 diabetes only. Medicaid must cover it for that purpose.
- Wegovy (semaglutide): Approved for weight loss, cardiovascular risk reduction, and type 2 diabetes. Coverage for weight loss is optional by state. Since March 2024, Medicaid must cover it when prescribed to reduce cardiovascular risk.
- Zepbound (tirzepatide): Approved for weight loss. Since December 2024, Medicaid must cover it when prescribed for moderate to severe obstructive sleep apnea in adults with obesity.
- Saxenda (liraglutide): Approved for chronic weight management. Coverage is optional by state.
This creates a practical reality: if you have both obesity and type 2 diabetes, your doctor can prescribe Ozempic or Mounjaro for diabetes management, and Medicaid is required to cover them. You’ll likely lose weight on these medications even though they aren’t officially prescribed for that purpose. If you have obesity alone without diabetes, your options are far more limited.
Coverage for Children Works Differently
Medicaid’s rules for children are more generous than for adults. Under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit, states must cover medications deemed medically necessary for children, including weight loss drugs. This means a child or adolescent on Medicaid may qualify for medications that the same state’s program would deny to an adult.
What Approval Looks Like in States That Cover It
Even in the 13 states that do cover GLP-1 medications for obesity, getting approved is not automatic. These drugs are typically subject to prior authorization, a process where your doctor must submit documentation proving you meet specific criteria before the prescription is filled.
Michigan offers a clear example of how strict these requirements can be. GLP-1 medications for weight management (including Saxenda, Wegovy, and Zepbound) are covered only for beneficiaries with a BMI of 40 or higher, which qualifies as morbid obesity. That threshold is significantly higher than the FDA label, which allows these drugs for people with a BMI of 30 or a BMI of 27 with a weight-related health condition. Michigan also requires adherence to a healthy lifestyle program before approving coverage.
Other states that cover these medications generally impose similar hurdles: documented participation in diet and exercise programs, specific BMI cutoffs, and periodic re-authorization to continue the prescription.
Older Weight Loss Pills and Medicaid
Before the GLP-1 era, several oral medications were approved for weight loss, including phentermine, phentermine-topiramate (Qsymia), and naltrexone-bupropion (Contrave). These older drugs are generally less expensive than the newer injectables, and some state Medicaid programs have historically been more willing to cover them.
When states do include weight loss medications on their formularies, the older oral drugs tend to land in lower cost tiers, meaning fewer barriers to access. The newer injectable GLP-1 medications, by contrast, are typically placed in higher tiers with stricter approval requirements. That said, the same state-by-state patchwork applies. Reviews of state Medicaid drug policies have consistently found that only a minority of states provide any coverage for obesity medications, whether old or new.
How to Find Out What Your State Covers
Because policies shift frequently (four states dropped coverage in a matter of months in late 2025), the most reliable way to check your current coverage is to contact your Medicaid plan directly. If you’re enrolled in a Medicaid managed care plan rather than fee-for-service Medicaid, your coverage may differ from the state’s baseline policy, since managed care organizations sometimes negotiate their own drug formularies.
Your doctor’s office can also run a prior authorization check, which will tell you whether a specific medication is covered under your plan and what documentation is needed. If your state doesn’t cover weight loss drugs but you have a qualifying condition like type 2 diabetes, cardiovascular disease, or sleep apnea, ask your doctor whether a medication approved for that condition could serve double duty.